Poster Sessions—Monday, September 24, 2018
P1.13-06 First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer

https://doi.org/10.1016/j.jtho.2018.08.863Get rights and content
Under an Elsevier user license
open archive

Cited by (0)